Answers are grounded in this paper and cite their sources.
Demonstrates improved risk screening in musculoskeletal disorders, suggesting scalable early diagnosis and personalized care.
Musculoskeletal disorders such as osteoarthritis (OA), rheumatoid arthritis (RA), and osteoporosis (OP) affect millions worldwide, often progressing silently until advanced stages. Accessible early risk stratification remains challenging because conventional diagnosis often depends on imaging, specialist evaluation, and fragmented clinical information. Herein, we developed Luma AI, a multimodal AI platform that integrates routine blood tests and demographic variables with curated patient‐reported symptom narratives. The text branch uses a domain‐specific clinical text encoder based on LoRA‐adapter‐fine‐tuned Bio_ClinicalBERT, whereas the structured branch uses optimized classical machine learning models. The two branches are fused through an explicit prediction‐score and text‐representation pipeline for early screening of OA, RA, and OP. Performance was validated using the U.S. NHANES and multi‐center Chinese cohorts. We evaluated more than 50 predictive models and applied Bayesian optimization to refine the structured models, achieving over 80% accuracy with structured data alone and exceeding 90% in the multimodal validation cohort when symptom narratives were included. The platform incorporates explainable AI tools to identify key risk factors and provides personalized post‐screening recommendations for lifestyle, diet, and medical follow‐up. This study demonstrates that Luma AI can support scalable low‐cost early risk screening and personalized management of OA, RA, and OP while remaining positioned as a risk‐stratification aid rather than a stand‐alone diagnostic replacement.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: